Member Info for Grailor

Exactly Ivy, this is also for all newly developed vaccines and is not specific or limited to Covid 19. It does, however, mean that HVIVO is in a great position wrt offering the facilities for the Major Pharma to undertake future challenge studies. So all good news!

Well I've topped up. Having been an HVIVO investor for a few years now, I am hoping that we will finally get what we have all been waiting for, a mulit bagger!! GLA

BDerby, go to Clintrials.gov.

The Market does not like these results!!

Now 45p - please someone explain this to me!!!!

Lol!!!

RB did you get back in at around 44p? If so you must be smiling now!!

Mmm. R&D costs down - no surprise as Flu-V is sat on the shelf and they have cancelled discovery stage projects.
Why are they only now going to speak to FDA and EMEA about Flu-V- more than a year after generating the Ph2b data, amazing?? There is obviously something putting off potential acquirers/partners.
I would guess that GSK's change in strategy was partly to blame for contract cancellations and agree an RNS would have been nice to inform us of these.
£2.4m R&D tax credit adds to the coffers but this will be significantly less next year, given the reduced R&D spend.
At least the BOD sees the company remaining as a 'going concern' for the next 12 months - small mercy's!!

Woodford get the wool pulled over his eyes....never! I think one strategy we should all have followed was to avoid anything Woodford put money into. Hindsight is a .......
I am an eternal optimist but even I am losing the will here. I am in the Biotech industry and, inmho, if anyone was going to acquire or partner for FLu-V it would have happened by now. Big pharma would have been all over this a year or more ago and whilst these deals can take time they can also be completed in a matter of weeks. ADYOR.

Hi PR, not very forthcoming then lol. The value of these assets is ebbing away as we speak - to delay starting the pivotal Ph3 studies for well over a year now is ridiculous.

Have to agree, this is getting phenomenally boring. We must all be missing something somewhere. Still hopes that GSK will swoop in!!! Well we can all dream.

HVIVO is a stock in the affected Woodford fund.

Mark, yes I know about drug dev timelines - been in the industry for over 30 years - but this is worrying. To have a potential blockbuster asset sat on the shelf doing nothing for 12 months is quite honestly ridiculous.
They may not run out of cash but they have nowhere near what is required to fund a Ph3 program. I for one would like an update on progress re negotiations for sale of the asset or for raising funds to undertake its future development.

Agreed Mon. One year post Ph2b results with no apparent activity is not a good sign whatsiever. BOD absolutely need to make some statement especially with the share price essentially at a 5year low!

I think we are all in the same boat! Unfortunately I am in a number of shares that Woodford is in and also hold shares in the Woodford Patient Capital Trust, for which I am now well down on as well.
I think its time for a holiday!!

Reaction to that 150k share sale - too small to be Woodford?

Yes, unfortunately it is.

Does appear that a number of shares that are included in Woodfords Funds are suffering in the aftermath of todays announcement.
What would certainly help here would be anything positive from the BOD - nearly a year now since the Flu-V Ph2 results were announced. Broken record ... I know, but at least let us know you are still alive and kicking.

We really could do with some sort of update - Flu-v has now been sat on the shelf for well over a year and is haemorrhaging value day on day.

RBT - I think we are on exactly the same page.